Early imatinib mesylate-induced hepatotoxicity in chronic myelogenous leukaemia

Jee Hyun Kong, Seung Hyun Yoo, Kyoung Eun Lee, Seung Hyun Nam, Jung Mi Kwon, Sang Min Lee, Hye Jung Chang, Moon Young Choi, Min Sun Cho, Yeung Chul Mun, Eunmi Nam, Soon Nam Lee, Chu Myong Seong

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Imatinib mesylate is the first molecule of targeted therapy in chronic myelogenous leukaemia inhibiting constitutively activated BCR-ABL kinase. There are no long-term follow-up studies of large sample sizes to assess the toxicity of the use of imatinib mesylate over 10 years. Several cases of hepatotoxicity, including fatal liver failure, have been associated with the long-term use of imatinib mesylate. We report here on a patient who experienced immediate dominant cholestatic damage of the liver and mild hepatocyte damage during imatinib mesylate therapy. This differs from most reports showing dominantly acute hepatitis with necrosis associated with the use of imatinib mesylate.

Original languageEnglish
Pages (from-to)205-208
Number of pages4
JournalActa Haematologica
Issue number4
StatePublished - Jan 2008


  • Chronic myelogenous leukaemia
  • Imatinib mesylate
  • Liver pathology


Dive into the research topics of 'Early imatinib mesylate-induced hepatotoxicity in chronic myelogenous leukaemia'. Together they form a unique fingerprint.

Cite this